---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-26-000193"
form_type: "8-K"
ticker: "AVXL"
cik: "0001314052"
company_name: "ANAVEX LIFE SCIENCES CORP."
filed_at: "2026-02-09T23:59:59+00:00"
generated_at: "2026-05-16T03:50:58.375438+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Anavex reports Q1 FY2026 net loss $5.7M; EU blarcamesine setback, re-examination ongoing

## Summary
- Net loss of $5.7M ($0.06 per share) vs. $12.1M ($0.14) in Q1 FY2025; R&D expenses dropped to $4.7M from $10.4M.
- Cash & equivalents $131.7M (up from $102.6M); company expects cash runway >3 years.
- EU CHMP issued negative opinion for blarcamesine in early Alzheimer's; Anavex requested EMA re-examination (Dec 2025).
- FDA Type C meeting in Jan 2026 showed interest; company will submit additional Phase IIb/III data for potential NDA.
- Appointed Wolfgang Liedtke as SVP Global Head of Neurology; joined ACCESS-AD initiative.

## SEC filing metadata
- accession: 0001731122-26-000193
- form_type: 8-K
- ticker: AVXL
- cik: 0001314052
- company_name: ANAVEX LIFE SCIENCES CORP.
- filed_at: 2026-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314052/000173112226000193/0001731122-26-000193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314052/000173112226000193/e7298_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-26-000193
- JSON: https://secwatch.observer/filing/0001731122-26-000193.json
- Plain text: https://secwatch.observer/filing/0001731122-26-000193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.